Korean Journal of Family Practice

Table. 4.

Treatments and clinical outcomes of patients infected with COVID-19

Variable National Institutes of Health clinical spectrum P-value
Total
(n=214)
Asymptomatic/mild illness
(n=104)
Moderate illness
(n=63)
Severe/critical illness
(n=47)
Treatment <0.001
Oxygen therapy 39 (18.2) 1 (1.0) 1 (1.6) 38 (80.9)
HFNC apply 7 (3.3) 0 (0) 0 (0) 7 (14.9)
Mechanical ventilation 1 (0.5) 0 (0) 0 (0) 1 (2.1)
Antiviral agent
Lopinavir/ritonavir 123 (57.5) 39 (37.5) 47 (74.6) 37 (78.7) <0.001
Hydroxychloroquine 31 (14.5) 7 (6.7) 10 (15.9) 14 (29.8) 0.001
Pneumonia on chest X-ray
Total 109 (50.9) 0 (0) 62 (98.4) 47 (100) <0.001
On admission 60 (28.0) 0 (0) 29 (46.0) 31 (66.0) <0.001
New onset during hospital stay 49 (22.9) 0 (0) 33 (52.4) 16 (34.0) <0.001
Discharge type <0.001
Normal dischargea 140 (65.4) 54 (51.9) 52 (82.5) 34 (72.3)
Residential treatment centersb 61 (28.5) 50 (48.1) 11 (17.5) 0 (0)
Transfer to tertiary hospital 11 (5.1) 0 (0) 0 (0) 11 (23.4)
Expire 2 (0.9) 0 (0) 0 (0) 2 (4.3)
Length of stay in hospital (d) 27.4±16.2 20.7±10.5 32.3±13.7 35.6±22.7 <0.001c

Values are presented as number (%) or mean±standard deviation.

COVID-19, coronavirus disease 2019; HFNC, high flow nasal cannula.

aA person should not exhibit fever without taking fever reducers and show improvements in clinical symptoms. Thereafter, the person should test negative on real-time RT-PCR tests twice in a row with at least a 24-hour interval. bMild cases who do not need hospitalization were shifted to residential treatment centers. cP-value by ANOVA.

P-value was calculated by chi-square test.

Korean J Fam Pract 2021;11:365~371 https://doi.org/10.21215/kjfp.2021.11.5.365
© KJFP